PLYX Stock News & Catalysts

FEATURED

Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200

New

PARAMUS, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX) ("Polaryx" or the "Company"), a clinical-stage biotechnology company developing novel, disease-modifying

Summary

Nov 9, 2026, 8:30 AM ·Globe Newswire

RECENT

Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer

Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles Appointment further strengthens clinical leadership and execution capabilities

Sep 1, 2026, 8:30 AM ·Globe Newswire

Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial

Company on track to initiate SOTERIA trial in the second half of 2026 Clinical development activities advancing following FDA authorization, CRO engagement and Fast Track Designation across all four planned indication

Aug 25, 2026, 8:30 AM ·Globe Newswire

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial

PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the "Company" or "Polaryx") (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare,

May 28, 2026, 8:30 AM ·Globe Newswire

Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards

PARAMUS, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders

May 14, 2026, 9:15 AM ·Globe Newswire

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference

PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage

Apr 23, 2026, 8:30 AM ·Globe Newswire

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference

Apr 23, 2026, 8:30 AM ·Globe Newswire

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that

Apr 21, 2026, 8:30 AM ·Globe Newswire

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care

PARAMUS, NJ, April 15, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage

Apr 15, 2026, 9:15 AM ·Globe Newswire

Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference

PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage

Apr 1, 2026, 8:30 AM ·Globe Newswire

Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)

Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc.

Mar 17, 2026, 8:30 AM ·Globe Newswire

Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events

PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage

Mar 12, 2026, 8:30 AM ·Globe Newswire

Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders

PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders

Feb 27, 2026, 8:30 AM ·Globe Newswire

Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial

PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage

Feb 17, 2026, 8:30 AM ·Globe Newswire

Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™

PARAMUS, NJ, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders

Feb 10, 2026, 8:30 AM ·Globe Newswire

Polaryx Therapeutics, Inc. Common Stock PLYX · News